Literature DB >> 28858290

Generation of high-purity human ventral midbrain dopaminergic progenitors for in vitro maturation and intracerebral transplantation.

Sara Nolbrant1, Andreas Heuer1, Malin Parmar1, Agnete Kirkeby1,2.   

Abstract

Generation of precisely patterned neural cells from human pluripotent stem cells (hPSCs) is instrumental in developing disease models and stem cell therapies. Here, we provide a detailed 16-d protocol for obtaining high-purity ventral midbrain (VM) dopamine (DA) progenitors for intracerebral transplantation into animal models and for in vitro maturation into neurons. We have successfully transplanted such cells into the rat; however, in principle, the cells can be used for transplantation into any animal model, and the protocol is designed to also be compatible with clinical transplantation into humans. We show how to precisely set the balance of patterning factors to obtain specifically the caudal VM progenitors that give rise to DA-rich grafts. By specifying how to perform quality control (QC), troubleshooting and adaptation of the procedure, this protocol will facilitate implementation in different laboratories and with a variety of hPSC lines. To facilitate reproducibility of experiments and enable shipping of cells between centers, we present a method for cryopreservation of the progenitors for subsequent direct transplantation or terminal differentiation into DA neurons. This protocol is free of xeno-derived products and can be performed under good manufacturing practice (GMP) conditions.

Entities:  

Mesh:

Year:  2017        PMID: 28858290     DOI: 10.1038/nprot.2017.078

Source DB:  PubMed          Journal:  Nat Protoc        ISSN: 1750-2799            Impact factor:   13.491


  20 in total

1.  Differences in neurogenic potential in floor plate cells along an anteroposterior location: midbrain dopaminergic neurons originate from mesencephalic floor plate cells.

Authors:  Yuichi Ono; Tomoya Nakatani; Yoshimasa Sakamoto; Eri Mizuhara; Yasuko Minaki; Minoru Kumai; Akiko Hamaguchi; Miyuki Nishimura; Yoko Inoue; Hideki Hayashi; Jun Takahashi; Toshio Imai
Journal:  Development       Date:  2007-08-01       Impact factor: 6.868

2.  Identification of midbrain floor plate radial glia-like cells as dopaminergic progenitors.

Authors:  Sonia Bonilla; Anita C Hall; Luisa Pinto; Alessio Attardo; Magdalena Götz; Wieland B Huttner; Ernest Arenas
Journal:  Glia       Date:  2008-06       Impact factor: 7.452

3.  Single-Cell Analysis Reveals a Close Relationship between Differentiating Dopamine and Subthalamic Nucleus Neuronal Lineages.

Authors:  Nigel Kee; Nikolaos Volakakis; Agnete Kirkeby; Lina Dahl; Helena Storvall; Sara Nolbrant; Laura Lahti; Åsa K Björklund; Linda Gillberg; Eliza Joodmardi; Rickard Sandberg; Malin Parmar; Thomas Perlmann
Journal:  Cell Stem Cell       Date:  2016-10-27       Impact factor: 24.633

4.  Dopaminergic differentiation of human embryonic stem cells.

Authors:  Xianmin Zeng; Jingli Cai; Jia Chen; Yongquan Luo; Zhi-Bing You; Erin Fotter; Yun Wang; Brandon Harvey; Takumi Miura; Cristina Backman; Guann-Juh Chen; Mahendra S Rao; William J Freed
Journal:  Stem Cells       Date:  2004       Impact factor: 6.277

5.  Generation of serotonin neurons from human pluripotent stem cells.

Authors:  Jianfeng Lu; Xuefei Zhong; Huisheng Liu; Ling Hao; Cindy Tzu-Ling Huang; Mohammad Amin Sherafat; Jeffrey Jones; Melvin Ayala; Lingjun Li; Su-Chun Zhang
Journal:  Nat Biotechnol       Date:  2015-12-14       Impact factor: 54.908

6.  Differentiation of spinal motor neurons from pluripotent human stem cells.

Authors:  Bao-Yang Hu; Su-Chun Zhang
Journal:  Nat Protoc       Date:  2009-08-20       Impact factor: 13.491

7.  Isolation and directed differentiation of neural crest stem cells derived from human embryonic stem cells.

Authors:  Gabsang Lee; Hyesoo Kim; Yechiel Elkabetz; George Al Shamy; Georgia Panagiotakos; Tiziano Barberi; Viviane Tabar; Lorenz Studer
Journal:  Nat Biotechnol       Date:  2007-11-25       Impact factor: 54.908

8.  Directed differentiation of forebrain GABA interneurons from human pluripotent stem cells.

Authors:  Yan Liu; Huisheng Liu; Conall Sauvey; Lin Yao; Ewa D Zarnowska; Su-Chun Zhang
Journal:  Nat Protoc       Date:  2013-08-08       Impact factor: 13.491

9.  Predictive Markers Guide Differentiation to Improve Graft Outcome in Clinical Translation of hESC-Based Therapy for Parkinson's Disease.

Authors:  Agnete Kirkeby; Sara Nolbrant; Katarina Tiklova; Andreas Heuer; Nigel Kee; Tiago Cardoso; Daniella Rylander Ottosson; Mariah J Lelos; Pedro Rifes; Stephen B Dunnett; Shane Grealish; Thomas Perlmann; Malin Parmar
Journal:  Cell Stem Cell       Date:  2016-10-27       Impact factor: 24.633

10.  Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling.

Authors:  Stuart M Chambers; Christopher A Fasano; Eirini P Papapetrou; Mark Tomishima; Michel Sadelain; Lorenz Studer
Journal:  Nat Biotechnol       Date:  2009-03-01       Impact factor: 54.908

View more
  60 in total

Review 1.  Pluripotent stem cell-based therapy for Parkinson's disease: Current status and future prospects.

Authors:  Kai-C Sonntag; Bin Song; Nayeon Lee; Jin Hyuk Jung; Young Cha; Pierre Leblanc; Carolyn Neff; Sek Won Kong; Bob S Carter; Jeffrey Schweitzer; Kwang-Soo Kim
Journal:  Prog Neurobiol       Date:  2018-04-11       Impact factor: 11.685

Review 2.  Induced pluripotent stem cells (iPSCs) as model to study inherited defects of neurotransmission in inborn errors of metabolism.

Authors:  Sabine Jung-Klawitter; Thomas Opladen
Journal:  J Inherit Metab Dis       Date:  2018-07-06       Impact factor: 4.982

Review 3.  Generation of defined neural populations from pluripotent stem cells.

Authors:  Sarah F McComish; Maeve A Caldwell
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2018-07-05       Impact factor: 6.237

4.  Long-Term Evaluation of Intranigral Transplantation of Human iPSC-Derived Dopamine Neurons in a Parkinson's Disease Mouse Model.

Authors:  Sébastien Brot; Nabila Pyrenina Thamrin; Marie-Laure Bonnet; Maureen Francheteau; Maëlig Patrigeon; Laure Belnoue; Afsaneh Gaillard
Journal:  Cells       Date:  2022-05-10       Impact factor: 7.666

Review 5.  Spotting-based differentiation of functional dopaminergic progenitors from human pluripotent stem cells.

Authors:  Jisun Kim; Jeha Jeon; Bin Song; Nayeon Lee; Sanghyeok Ko; Young Cha; Pierre Leblanc; Hyemyung Seo; Kwang-Soo Kim
Journal:  Nat Protoc       Date:  2022-02-09       Impact factor: 17.021

6.  An integrated biomanufacturing platform for the large-scale expansion and neuronal differentiation of human pluripotent stem cell-derived neural progenitor cells.

Authors:  Gayathri Srinivasan; Daylin Morgan; Divya Varun; Nicholas Brookhouser; David A Brafman
Journal:  Acta Biomater       Date:  2018-05-15       Impact factor: 8.947

7.  Pluripotent Stem Cell Derived Neurons as In Vitro Models for Studying Autosomal Recessive Parkinson's Disease (ARPD): PLA2G6 and Other Gene Loci.

Authors:  Renjitha Gopurappilly
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

8.  Spatial RNA Sequencing Identifies Robust Markers of Vulnerable and Resistant Human Midbrain Dopamine Neurons and Their Expression in Parkinson's Disease.

Authors:  Julio Aguila; Shangli Cheng; Nigel Kee; Ming Cao; Menghan Wang; Qiaolin Deng; Eva Hedlund
Journal:  Front Mol Neurosci       Date:  2021-07-08       Impact factor: 5.639

9.  Generation of Cortical, Dopaminergic, Motor, and Sensory Neurons from Human Pluripotent Stem Cells.

Authors:  Shermaine Huiping Tay; Zi Jian Khong; Yong Hui Koh; Shi Yan Ng
Journal:  Methods Mol Biol       Date:  2022

10.  Grafts Derived from an α-Synuclein Triplication Patient Mediate Functional Recovery but Develop Disease-Associated Pathology in the 6-OHDA Model of Parkinson's Disease.

Authors:  Shelby Shrigley; Fredrik Nilsson; Bengt Mattsson; Alessandro Fiorenzano; Janitha Mudannayake; Andreas Bruzelius; Daniella Rylander Ottosson; Anders Björklund; Deirdre B Hoban; Malin Parmar
Journal:  J Parkinsons Dis       Date:  2021       Impact factor: 5.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.